Barclays Brief Weight loss drugs: Scaling up
8 snips
Mar 3, 2026 Emily Field, a US biopharmaceuticals equity research analyst focused on obesity therapeutics, breaks down the market transformation driven by GLP-1s. She explains why oral pills will expand the treated population. She discusses pricing pressure, direct‑to‑consumer moves and who might enter the market. She flags commercial capability and upcoming launches as key milestones.
AI Snips
Chapters
Transcript
Episode notes
Obesity Medicines Could Become A Hundred Billion Market
- Weight loss drugs could reach a very large market with obesity potentially a $100bn opportunity by 2030.
- Emily Field notes Zetbound and Munjaro alone could top $50bn this year and she sees no reason to lower earlier $100bn obesity market estimates.
Oral Pills Are Market Openers Not Just Cannibals
- Oral obesity drugs are likely to expand the treated population rather than simply cannibalize injectables.
- Emily Field argues many current injectable users will stay on weekly jabs while pills attract needle-phobic patients and open ex-US markets lacking cold chain.
Watch Oral Launch Timing And Early Uptake
- Monitor the timing and uptake of oral launches as a near-term investor signal.
- Emily highlights Novo's pill already launched and Eli Lilly's pill due in Q2 as the key data points that will drive stock performance.